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Abstract
Inhibition of nitric oxide (NO) signaling may contribute to pathological activation of the vas-
cular endothelium during severe malaria infection. Dimethylarginine dimethylaminohydro-
lase (DDAH) regulates endothelial NO synthesis by maintaining homeostasis between
asymmetric dimethylarginine (ADMA), an endogenous NO synthase (NOS) inhibitor, and
arginine, the NOS substrate. We carried out a community-based case-control study of Gam-
bian children to determine whether ADMA and arginine homeostasis is disrupted during
severe or uncomplicated malaria infections. Circulating plasma levels of ADMA and argi-
nine were determined at initial presentation and 28 days later. Plasma ADMA/arginine ratios
were elevated in children with acute severe malaria compared to 28-day follow-up values
and compared to children with uncomplicated malaria or healthy children (p<0.0001 for
each comparison). To test the hypothesis that DDAH1 is inactivated during Plasmodium
infection, we examined DDAH1 in a mouse model of severe malaria. Plasmodium berghei
ANKA infection inactivated hepatic DDAH1 via a post-transcriptional mechanism as evi-
denced by stable mRNA transcript number, decreased DDAH1 protein concentration,
decreased enzyme activity, elevated tissue ADMA, elevated ADMA/arginine ratio in
plasma, and decreased whole blood nitrite concentration. Loss of hepatic DDAH1 activity
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and disruption of ADMA/arginine homeostasis may contribute to severe malaria pathogene-
sis by inhibiting NO synthesis.
Author Summary
During a malaria infection, the vascular endothelium becomes more adhesive, permeable,
and prone to trigger blood clotting. These changes help the parasite adhere to blood ves-
sels, but endanger the host by obstructing blood flow through small vessels. Endothelial
nitric oxide (NO) would normally counteract these pathological changes, but NO signal-
ling is diminished malaria. NO synthesis is inhibited by asymmetric dimethylarginine
(ADMA), a methylated derivative of arginine that is released during normal protein turn-
over. We found the ratio of ADMA to arginine to be elevated in Gambian children with
severe malaria, a metabolic disturbance known to inhibit NO synthesis. ADMA was asso-
ciated with markers of endothelial activation and impaired tissue perfusion. In parallel
experiments using mice, the enzyme responsible for metabolizing ADMA, dimethylargi-
nine dimethylaminohydrolase (DDAH), was inactivated after infection with a rodent
malaria. Based on these studies, we propose that decreased metabolism of ADMA by
DDAHmight contribute to the elevated ADMA/arginine ratio observed during an acute
episode of malaria. Strategies to preserve or increase DDAH activity might improve NO
synthesis and help to prevent the vascular manifestations of severe malaria.
Introduction
Current estimates of world-wide mortality due to malaria range from 367,000 to 755,000
deaths per year, mostly in African children [1,2]. Prompt treatment with parenteral artesunate
improves survival in children with severe malaria but mortality remains high in those present-
ing with complications such as coma or acidosis [3]. Development of effective therapies for
these patients will require improved understanding of the pathophysiology of severe malaria.
Patients with severe malaria exhibit impaired endothelium-dependent vasodilation [4] and
reduced nitrite and nitrate concentrations in plasma and urine [5], indicating decreased nitric
oxide synthesis. Impaired NO signalling has been implicated in microcirculatory dysfunction [6],
loss of blood-brain barrier integrity [7,8] and cytoadherence of infected erythrocytes to the vascu-
lar endothelium in mice [9]. Similar pathology has been directly observed in human malaria, but
the importance of NO signalling in these processes is less certain [10–13]. NO production by nitric
oxide synthase (NOS) is dependent in part on the relative bioavailability of arginine, the NOS sub-
strate, and asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor released during
hydrolysis of proteins that have been methylated by protein arginine methyltransferase [14–16]
(Fig 1). By inhibiting NOS, ADMA not only causes vasoconstriction, increased blood pressure,
increased systemic vascular resistance and decreased forearm blood flow in vivo [17–19], but also
affects adhesion, inflammation, thrombosis, barrier integrity, motility, growth and repair in vitro
[20–31]–endothelial functions that are relevant to the pathophysiology of malaria.
Dimethylarginine dimethylaminohydrolase 1 (DDAH1) metabolizes ADMA at a rate
inversely proportional to arginine concentration [32] and thus stabilizes the ratio of ADMA
to arginine when arginine levels vary [33,34]. In Gambian children, an intronic DDAH1 poly-
morphism is associated with susceptibility to severe malaria [35], raising the possibility that
DDAH1 might be functionally linked to disrupted ADMA/arginine homeostasis and impaired
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NO synthesis in severe malaria. In this study, we identify dysregulation of ADMA/arginine
homeostasis in Gambian children with severe malaria and hypothesize that ADMA clearance
is impaired by hepatic DDAH1 inactivation. To test this hypothesis, we infected mice with P.
berghei ANKA and assessed changes in DDAH1 expression, protein levels and activity in
hepatic tissue, a major site of ADMAmetabolism [29,36–38].
Results
ADMA/Arginine Homeostasis Is Disrupted in Gambian Children with
Severe Malaria
We determined ADMA and arginine concentrations in blood plasma obtained from Gambian
children with severe or uncomplicated malaria at initial presentation and 28 days later. Healthy
afebrile aparasitemic Gambian children served as an additional control group. Baseline charac-
teristics of the study populations are presented in Table 1.
Fig 1. DDAH regulates NO synthesis via ADMAmetabolism. Protein arginine methyltransferases
(PRMTs) methylate arginine (Arg) residues on proteins to form asymmetric dimethylarginine (ADMA).
Proteolysis releases free ADMA that inhibits nitric oxide synthase (NOS). Dimethylarginine
dimethylaminohydrolase (DDAH) metabolizes free ADMA to citrulline (Cit) that can be recycled to arginine.
Inactivation of DDAH leads to accumulation of ADMA, inhibition of endothelial NO synthesis, and endothelial
dysfunction.
doi:10.1371/journal.ppat.1005119.g001
Table 1. Baseline clinical characteristics of the study population.
Healthy Gambian Children Uncomplicated Malaria Severe Malaria
Number Enrolled 31 102 96
Age, years 7 [4.5–9.5] 7 [4.0–11.0] 4 [2.7–5.1]a,b
Weight, kg 18 [13.5–26.5] 19.3 [14.0–26.0] 14.0 [11.0–16.0]a,b
Temperature, °C 36.8 [36.6–37.0] 38.0 [36.8–38.7]a 38.6 [38.1–39.4]a,b
Respiration rate, breaths/min - 36 [28–48] 48 [38–60]b
Hemoglobin, g/dL - 11.3 [10.2–12.7] 9.7 [7.0–10.8]b
Parasitemia, % - 2.9 [1.0–6.2] 9.2 [4.8–17.4]b
PfHRP2, ng/mL - 118 [54–226] 249 [133–605]b
Glucose, mmol/L - 6 [4.9–6.7] 6.8 [5.3–8.5]
Lactate, mmol/L - 2.8 [2.2–4.1] 5.0 [3.2–7.0]b
sVCAM, ng/mL 905 [773–1078] 905 [726–1313] 1266 [828–1798]b
Haptoglobin, mg/dL 44.5 [15.6–79.9] 1.3 [0.0–49.3]a 0.0 [0.0–4.1]a
Values are presented as median [interquartile range]. ADMA: asymmetric dimethylarginine, sVCAM: soluble vascular cell adhesion molecule, PfHRP2: P.
falciparum histidine-rich protein 2.
a p < 0.001 compared to healthy Gambian children by Mann-Whitney test.
b p < 0.001 compared to uncomplicated malaria by Mann-Whitney test.
doi:10.1371/journal.ppat.1005119.t001
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Plasma ADMA was lower in children with severe malaria (median [IQR]: 0.40 [0.30–0.51]
μmol/L) or uncomplicated malaria (0.40 [0.33–0.47] μmol/L) compared to healthy children
(0.61 [0.56–0.69] μmol/L, p< 0.0001 vs. uncomplicated; p< 0.0001 vs. severe; Fig 2 and
Table 2). ADMA remained low at the 28-day follow-up visit for patients recovered from
malaria. Plasma arginine was profoundly depleted in children with severe malaria compared to
children with uncomplicated malaria or healthy children (severe malaria: 31.7 [23.0–40.6]
μmol/L; uncomplicated malaria: 45.0 [35.4–55.7] μmol/L, p< 0.0001 vs severe; healthy:
Fig 2. The ADMA/arginine ratio is acutely elevated in African children with severe malaria. ADMA and
arginine concentrations were measured in plasma samples collected at the time of presentation (Day 0) and
at follow-up visits 28 days later (Day 28) in children with WHO-defined uncomplicated malaria or severe
malaria. Healthy Gambian children served as a reference group. Wilcoxon test was used for pair-wise
comparison of admission and day 28 mesurements within individuals (47 paired observations from patients
with severe malaria; 65 paired observations from patients with uncomplicated malaria). Mann-Whitney test
was used to compare patients with severe malaria (n = 81) versus uncomplicated malaria (n = 75) and to
compare patients with uncomplicated malaria versus healthy children (n = 31). Each horizontal line depicts
the group median. **** p < 0.0001; ns p > 0.05.
doi:10.1371/journal.ppat.1005119.g002
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88.7 [79.3–102.5] μmol/L, p< 0.0001 vs severe; Fig 2 and Table 2). By the 28-day follow up
visit, plasma arginine concentration increased to 56.7 [42.1–78.9] μmol/L among children who
recovered from severe malaria and to 70.8 [58.6–85.1] μmol/L among children who recovered
from uncomplicated malaria (p< 0.0001 vs acute, Fig 2), but remained lower than the arginine
concentration observed in healthy Gambian children (88.7 μmol/L; p< 0.0001 for either
comparison).
ADMA is a competitive inhibitor of NOS, and the ratio of ADMA to arginine determines
NOS activity [39]. The ratio of ADMA to arginine was elevated among children with severe
malaria (13.5 [11.2–17.1] ×10−3) compared to children with uncomplicated malaria (8.8 [7.2–
11.6] ×10−3, p< 0.0001) or healthy children (6.7 [5.8–8.2] ×10−3, p< 0.0001, Fig 2). After
recovery from severe malaria, the ADMA/arginine ratio returned to the level observed in
healthy Gambian children (recovered from severe malaria: 7.4 [5.9–10.1] ×10−3, p< 0.0001 vs.
acute; p = 0.25 vs. healthy children; Fig 2 and Table 2). Thus elevation of the ADMA/arginine
ratio appears to be an acute metabolic disturbance associated with a symptomatic episode of
malaria (modeled in S2 Fig).
Relationships between Arginine Metabolites and Biomarkers of Malaria
Severity
In healthy Gambian children, plasma ADMA concentration was correlated with plasma argi-
nine concentration (r = 0.43, p< 0.05); children with lower arginine tended to have lower
ADMA (S1 Fig). In children with uncomplicated malaria, the correlation was stronger
(r = 0.59, p< 0.0001) and the slope of the linear regression was steeper (p< 0.0001 vs healthy;
S1 Fig). In children with severe malaria, the correlation was stronger (r = 0.77, p< 0.0001) and
the slope of the linear regression was steeper still (p< 0.0001 vs uncomplicated; S1 Fig). At the
day 28 follow up visit, the relationship between ADMA and arginine (ie, the slopes of the linear
regressions) had returned to normal (S1 Fig), though the absolute levels of ADMA and arginine
remained lower than in health children.
Lactate is a biomarker of impaired tissue perfusion that is associated with mortality from
severe malaria in children [40–43]. In our study, lactate (median [IQR]) was elevated in chil-
dren with severe malaria (5.0 [3.2–7.0] mmol/L) compared to children with uncomplicated
malaria (2.8 [2.2–4.1] mmol/L, p< 0.0001, Table 1). Lactate correlated positively with ADMA
among children with severe malaria (r = 0.34, p = 0.004, S3 Fig), implying that tissue perfusion
was impaired among those with higher ADMA levels. Lactate did not correlate with arginine
(r = 0.16, p = 0.20, S3 Fig) but did correlate with the ADMA/arginine ratio (r = 0.28, p = 0.02,
Table 2. ADMA and arginine concentrations in plasma.
Healthy Gambian Children Uncomplicated Malaria Severe Malaria
Day 0 Day 28 Day 0 Day 28
n = 31 n = 75 n = 65 n = 81 n = 47
ADMA, μmol/L 0.61 [0.56–0.69] 0.40 [0.33–0.47]a 0.40 [0.33–0.47] 0.40 [0.30–0.51]a 0.44 [0.37–0.50]
Arginine, μmol/L 88.7 [79.3–102.5] 45.0 [35.4–55.7]a 70.8 [58.6–85.1]c 31.7 [23.0–40.6]a,b 56.7 [42.1–78.9]c
ADMA/Arg x 10−3 6.7 [5.8–8.2] 8.8 [7.2–11.6]a 5.7 [4.8–6.8]c 13.5 [11.2–17.1]a,b 7.4 [5.9–10.1]c
Values are presented as median [interquartile range]. ADMA: asymmetric dimethylarginine. Day 0 was the day of initial presentation to clinic or hospital.
a p < 0.0001 compared to healthy Gambian children by Mann-Whitney test.
b p < 0.0001 compared to uncomplicated malaria by Mann-Whitney test.
c p < 0.0001 compared to admission by Wilcoxon matched-pairs signed-rank test.
doi:10.1371/journal.ppat.1005119.t002
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Table 3). In multiple linear regression analysis using ADMA and arginine as explanatory vari-
ables, ADMA was positively related to lactate (β = 0.758, p = 0.002) while arginine was nega-
tively and non-significantly related to lactate (β = -0.393, p = 0.09; Table 4).
We measured soluble vascular cell adhesion molecule (sVCAM) as a biomarker of endothe-
lial activation. Plasma sVCAM was elevated in children with severe malaria at the time of
admission compared to children with uncomplicated malaria or healthy children (severe
malaria admission: 1266 [828–1798] ng/mL; acute uncomplicated: 905 [726–1313] ng/mL,
p< 0.05 vs severe, healthy children: 905 [773–1078] ng/mL, p< 0.05 vs severe, Table 1).
sVCAM returned to normal at day 28 among children who had severe malaria (841 [655–
1147] ng/mL, p< 0.001 vs admission). In contrast, the sVCAM level of children with uncom-
plicated malaria was similar to the level measured in healthy children (p = 0.84). Endothelial
activation appears to be a distinctive feature of acute severe malaria.
Soluble VCAM was positively correlated with plasma ADMA in severe malaria patients
(r = 0.60, p< 0.0001, Table 3 and S3 Fig). This observation suggests that ADMA, a NOS inhib-
itor, is associated with endothelial activation and release of sVCAM into circulation. sVCAM
was also positively correlated with arginine (r = 0.59, p< 0.0001, Table 3 and S3 Fig). In multi-
ple linear regression analysis, ADMA (β = +0.413, p = 0.02) was more significantly related to
sVCAM levels than was arginine (β = +0.332, p = 0.06; Table 4).
Table 4. Multiple linear regression analysis of the relationships between ADMA and arginine and hemoglobin, HRP2, sVCAM, or lactate.
Explanatory Variables
ADMA Arg Overall Model
Dependent Variable beta p beta p R2 df p
Hemoglobin -3.039 0.003 +0.404 0.66 0.20 76 0.0002
HRP2 +0.302 0.53 +0.001 0.99 0.03 36 0.53
sVCAM +0.413 0.02 +0.332 0.06 0.41 58 0.0000003
Lactate +0.758 0.002 -0.393 0.09 0.15 68 0.004
ADMA, Arg, HRP2, and sVCAM were natural log-transformed. Lactate was square root-transformed. ADMA and arginine were explanatory variables in
four separate linear models predicting hemoglobin, HRP2, sVCAM, or Lactate.
doi:10.1371/journal.ppat.1005119.t004
Table 3. Correlation of ADMAwith biomarkers of anemia, hemolysis, parasite biomass, endothelial activity, and tissue perfusion among children
with severe malaria.
ADMA Arg ADMA/Arg
df r p r p r p
Hemoglobin 77 -0.44 0.00004 -0.32 0.004 -0.14 0.21
Haptoglobin 59 -0.29 0.02 -0.24 0.06 -0.05 0.72
HRP2 37 +0.18 0.26 +0.15 0.35 +0.05 0.78
sVCAM 59 +0.60 0.0000002 +0.59 0.0000005 +0.02 0.90
Lactate 69 +0.34 0.004 +0.16 0.20 +0.28 0.02
ADMA, Arg, ADMA/Arg, HRP2 and sVCAM were natural log-transformed. Hemoglobin was normally distributed and was not transformed. Lactate was
square root-transformed. Haptoglobin could not be transformed to a normally distributed variable. All correlations were calculated using Pearson’s method,
except for correlations with haptoglobin which were calculated using Spearman’s method. A plot of each correlation is presented in the supplement (S3
Fig).
doi:10.1371/journal.ppat.1005119.t003
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Haptoglobin becomes depleted from plasma during acute intravascular hemolysis [44].
Haptoglobin was low at the time of admission in children with severe malaria or uncompli-
cated malaria (severe: 0 [0–4.1] mg/dL; uncomplicated: 1.3 [0–49.3] mg/dL), and increased by
the 28-day follow up visit (severe day 28: 13.8 [1.2–44.3] md/dL, p< 0.0001 vs admission;
uncomplicated day 28: 18.7 [0.2–59.4] mg/dL, p< 0.07 vs admission). Admission haptoglobin
values, but not day 28 values, were significantly lower than in healthy children (44.5 [15.6–
79.9] mg/dL).
Because haptoglobin was undetectable in many children with severe malaria, we analyzed
the correlation with ADMA and arginine using Spearman’s method. The correlation between
haptoglobin and ADMA was weak (r = -0.29, p = 0.02, Table 3 and S3 Fig), and weaker still
with arginine (r = -0.24, p = 0.06, Table 3 and S3 Fig). There were however, moderate negative
correlations with hemoglobin, a measure of anemia that may be partially reflective of hemolysis
(correlation with Hb and ADMA: r = -0.44, p<0.0001; Hb and Arg r = -0.32, p = 0.004;
Table 3 and S3 Fig). Multiple linear regression analysis again revealed that this correlation was
Fig 3. (A-D) Plasmodium bergheiANKA infection increases the plasma ratio of ADMA to arginine in mice. HPLC was used to determine (A) ADMA,
(B) arginine concentrations, and (C) ADMA/Arg ratio in plasma samples; (D) gas phase chemiluminescent assay was used to determine nitrite concentration
in blood. Blood was obtained frommice 6 days after inoculation with P. berghei ANKA (n = 23) and from uninfected control mice (n = 28) in 3 independent
experiments. (E-H) Plasmodium berghei ANKA infection decreases hepatic DDAH activity in mice. (E)Quantitative RT-PCRwas performed to assess
hepatic Ddah1 expression 6 days after inoculation with P. berghei ANKA. Values were normalized toGapdhmRNA transcripts and expressed as fold-change
vs. control values. Liver samples were obtained from 12 control mice and 12 infected mice representing 2 independent inoculation experiments. (F)Western
blot was used to detect hepatic DDAH1 protein (38 kDa) in liver tissue obtained frommice 6 days after inoculation with P. berghei ANKA and from uninfected
control mice. β-actin (42 kDa) was used as an internal control. Densitometry was used to quantify DDAH1 band density normalized to β-actin and expressed
as fold-change vs. control values. Data are pooled from 12 control mice and 12 infected mice representing 3 independent experiments. (G) DDAH activity
was assessed by quantification of L-citrulline production by liver homogenates in the presence of saturating concentrations of ADMA substrate (2.5 mM). L-
citrulline production was calculated on a per-hour basis and normalized to protein content. (H) Intracellular hepatic ADMA was assessed by HPLC in liver
homogenates and normalized to protein content. Liver samples were collected frommice 6 days after inoculation with P. berghei ANKA (n = 25) and from
uninfected control mice (n = 28). Results were pooled from 3 independent experiments. Boxes indicate median, 25th and 75th percentiles. Values greater than
1.5 times the IQR are plotted as individual points (Tukey’s method). Mann-Whitney test was used to compare groups.
doi:10.1371/journal.ppat.1005119.g003
DDAH Inactivation in Severe Malaria
PLOS Pathogens | DOI:10.1371/journal.ppat.1005119 September 25, 2015 7 / 20
primarily due to the association of hemoglobin with ADMA (β = -3.039, p = 0.003) and not
with arginine (β = +0.404, p = 0.66; Table 4).
P. falciparum histidine-rich protein 2 (PfHRP2), a circulating marker of parasite biomass,
was higher in children with severe malaria compared to uncomplicated malaria (severe: 249
[133–605] ng/mL vs uncomplicated: 118[54–226] ng/mL, p = 0.0001, Table 1). However,
PfHRP2 was not correlated with ADMA or arginine (Table 3; S3 Fig).
Plasmodium berghei Infection Alters Plasma ADMA/Arginine
Homeostasis and Blood Nitrite Levels
To determine whether P. berghei infection was associated with systemic changes in ADMA and
arginine, we analyzed plasma from P. berghei ANKA-infected mice. Similar to Gambian chil-
dren with malaria, plasma ADMA concentrations were lower in infected animals compared to
uninfected controls on day 6 post-inoculation (0.44 [0.40–0.49] vs. 0.59 [0.54–0.63] μmol/L,
p< 0.0001, Fig 3A). Arginine concentrations were also lower in infected mice compared to
uninfected controls (46.7 [39.2–53.3] vs. 78.1 [66.5–101.9] μmol/L, p<0.0001, Fig 3B). Argi-
nine decreased to a greater extent than ADMA, resulting in an increased ratio of ADMA to
arginine among infected mice (9.83 [8.65–12.49] ×10−3 vs. 7.10 [5.94–8.81] ×10−3, p<0.0001,
Fig 3C). The murine findings recapitulated our observations in Gambian children with
malaria.
Whole blood nitrite is reflective of NOS activity [45]. We determined nitrite concentrations
in whole blood samples from P. berghei ANKA-infected mice and uninfected controls using a
gas-phase chemiluminescent assay. Whole blood nitrite was decreased in infected mice (0.36
[0.28–0.45] μmol/L) compared with uninfected controls (0.49 [0.41–0.71] μmol/L, p = 0.0001,
Fig 3D), suggesting that P berghei ANKA infection causes a decrease in systemic NO produc-
tion in mice.
Plasmodium berghei Infection Decreases DDAH1 Abundance in Hepatic
Tissue
DDAH1 is highly active in the liver and plays a key role in regulating circulating levels of
ADMA [29,33,36–38]. To determine whether severe malaria affects hepatic DDAH1 function,
we assessed hepatic Ddah1 gene expression and protein levels in liver tissue from C57BL/6
mice 6 days after inoculation with P. berghei ANKA. Using quantitative RT-PCR to assess
hepatic Ddah1mRNA transcript number relative to Gapdh, we found that Ddah1 gene expres-
sion was not changed by P. berghei ANKA infection (median [IQR] fold change: 1.1 [1.0–1.1],
p = 0.07, Fig 3E). In contrast, Western blot analysis revealed a decrease in hepatic DDAH1 pro-
tein from P. berghei ANKA-infected mice compared to uninfected control mice (median [IQR]
fold change: 0.33 [0.28–0.46], p< 0.0001, Fig 3F). These data demonstrate that P. berghei
ANKA infection decreases DDAH1 protein abundance by a post-transcriptional mechanism.
Plasmodium berghei Infection Decreases DDAH1 Metabolism of ADMA
to Citrulline
To determine the functional impact of hepatic DDAH1 inactivation by Plasmodium infection,
we quantified ADMA clearance in liver homogenates by measuring the rate of de novo citrul-
line production in the presence of saturating concentrations of ADMA substrate (assay valida-
tion presented in S5 Fig). Hepatic ADMA clearance was lower in mice infected with P. berghei
ANKA compared with uninfected controls (infected: 3.83 [3.22–4.19] nmol citrulline × mg
protein-1 × hr-1 vs uninfected control: 6.48 [5.23–7.49] nmol citrulline × mg protein-1 × hr-1,
DDAH Inactivation in Severe Malaria
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p< 0.0001, Fig 3G). To assess the impact of P. berghei infection on hepatic ADMAmetabo-
lism, we determined intracellular ADMA concentrations in PBS-perfused liver samples from
infected and control mice. ADMA was increased in liver tissue from infected mice compared
with uninfected controls (infected: 126.5 [88.9–198.2] pmol/mg protein vs uninfected control:
49.7 [35.3–77.8] pmol/mg protein, p< 0.0001, Fig 3H).
We calculated the correlation between hepatic DDAH activity and hepatic ADMA concen-
tration in healthy mice and found a positive correlation (r = 0.46, p = 0.01), i.e., hepatic DDAH
activities were greater in mice that had higher tissue levels of ADMA. This may reflect induc-
tion of DDAH activity in response to tissue levels of ADMA. Among P. berghei-infected mice,
the correlation was similar (r = 0.42, p = 0.04) though the tissue levels of ADMA were higher,
and the DDAH activities were lower than in uninfected mice (S4 Fig and S1 Table). The partial
correlation coefficient between hepatic DDAH activity and hepatic ADMA concentration,
accounting for infection status, remained positive (rpart = 0.34, p = 0.01). We also calculated
the correlation between hepatic DDAH activity and plasma ADMA/Arginine ratio in mice,
and found a negative trend, i.e., mice with lower DDAH activity tended to have higher ADMA/
Arginine ratios in plasma (rpart = -0.23, p = 0.09; S4 Fig and S1 Table).
Discussion
We have analyzed ADMA and arginine concentrations in plasma from children with severe
malaria to determine whether malaria is associated with disruption of ADMA/arginine homeo-
stasis. We found that children with acute severe malaria have uncompensated hypoarginine-
mia, i.e., low arginine with an elevated ADMA/arginine ratio. The hypoargininemia persisted
over the 28 days of follow-up, while the ratio of ADMA to arginine returned to normal. We
interpret this as a transient inability to metabolize ADMA at a sufficient rate to compensate for
low arginine during acute infection. Although plasma ADMA levels were below normal in
patients with severe malaria, ADMA was positively correlated with lactate, a biomarker of
severity, and sVCAM, a biomarker of endothelial activation, suggesting that higher ADMA lev-
els are associated with adverse pathophysiologic changes. DDAH1 metabolizes ADMA, so we
examined changes in DDAH1 activity in mice infected with a Plasmodium berghei ANKA, a
model of severe malaria. P berghei infection caused inactivation of hepatic DDAH1, accumula-
tion of intracellular ADMA in liver tissue, elevation of the ADMA to arginine ratio in plasma,
and decreased levels of nitrite in blood. Although these findings in the mouse model cannot be
directly extrapolated to human malaria, it raises the possibility that the elevated ADMA/argi-
nine ratio observed in children with severe malaria could be due in part to inactivation of
DDAH1.
Our results extend upon a previous report of ADMA and arginine levels in Tanzanian chil-
dren. Weinberg et al. observed ADMA/arginine ratios of 13.2 [11.1–16.4] ×10−3 in cerebral
malaria, 12.3 [10.0–15.1] ×10−3 in non-cerebral severe malaria, 12.6 [10.7–15.1] ×10−3 in mod-
erately severe malaria and 7.1 [5.8–9.0] ×10−3 in healthy children [46]. These values are consis-
tent with the ADMA/arginine ratios observed in our study. We found the ADMA/arginine
ratio to be significantly greater in children with severe malaria compared to children with
uncomplicated malaria, while Weinberg et al found no differences among the ADMA/arginine
ratios of cerebral malaria, non-cerebral severe malaria and moderately severe malaria groups.
This discrepancy may be explained by the increased severity of the moderately severe malaria
group in Weinberg, et al. that differed from our uncomplicated group by the inclusion of
patients who could not tolerate oral medication [46]. As a result, these children may have had
greater dietary insufficiency of arginine and arginine precursors than our group of uncompli-
cated malaria patients. Although the plasma arginine concentration was lower in Gambian
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children with severe malaria compared to the Tanzanian children with cerebral malaria, the
rise from admission to day 28 in the Gambian children (31.7 to 56.7 umol/L, an increase of 25
umol/L) was similar to the rise from admission to day 7 in the Tanzanian children (45 umol/l
to 70 umol/L, an increase of 25 umol/L).
In both Gambian and Tanzanian children with severe malaria, ADMA and the ADMA/Arg
ratio were each correlated with lactate. This could be mediated through the vasoconstrictive or
pro-adhesive effects of ADMA on vascular endothelium especially in the setting of hypoargine-
mia, with subsequent impairment of tissue perfusion leading to anaerobic glycolysis and lactate
generation. Inter-individual differences in hepatic blood flow could also be responsible for the
strong correlation between ADMA and lactate, since the clearance of each is dependent on
hepatic perfusion. Impaired perfusion of liver tissue has been observed in adults with severe
malaria [47] and could limit hepatic clearance of plasma ADMA [33,36–38].
In both Gambian and Tanzanian children with severe malaria, ADMA was correlated with
biomarkers of endothelial activation (sVCAM and Angiopoietin-2, respectively). This could be
through direct effects of ADMA on endothelial cells [48] or via the pro-adhesive effects of
ADMA on circulating immune cells that interact with endothelium [49,50].
P. falciparum histidine-rich protein 2 (PfHRP2) has been previously assessed as a quantita-
tive marker of parasite biomass [51,52]. PfHRP2 did not correlate significantly with ADMA,
arginine or the ADMA/arginine ratio among children with severe or uncomplicated malaria
(Table 3). Our findings are in agreement with the prior study [46] and together suggest that in
children host ADMAmetabolism is not determined by parasite biomass.
Arginine depletion and disruption of ADMA/arginine homeostasis have also been observed
in adults with moderately severe and severe malaria [53]. In contrast to African children, Indo-
nesian adults with severe malaria demonstrated elevated ADMA [53]. The apparent discrep-
ancy in plasma ADMA in children and adults with severe malaria might be explained by
differences in severe malaria pathophysiology observed in older versus younger patients [54].
Changes in plasma ADMA also differ between children and adults with acute sepsis; compared
to age-matched healthy controls, ADMA was decreased in pediatric sepsis, but studies of adult
sepsis found ADMA to be either unchanged or increased [55–58].
Disruption of ADMA/arginine homeostasis in children with severe malaria could be due to
increased protein methylation, accelerated proteolysis of methylated proteins or impaired
clearance of free ADMA. One might expect plasma ADMA to be directly elevated during a
severe malaria infection, due to the combination of increased release of ADMA from erythro-
cytes undergoing hemolysis [59] and the impaired activity of hepatic DDAH that we present
here. Instead, we observed lower plasma ADMA concentrations in both human and mouse
malaria, consistent with prior measurements in children with malaria [46]. This could be due
to increased uptake of ADMA from plasma into cellular compartments as has been observed in
vitro after LPS, TNF or IL-1 stimulation [60]. In addition, plasma ADMA was strongly corre-
lated with plasma arginine in our study, suggesting that arginine deficiency might lead to lower
plasma ADMA. Mechanisms that could potentially link plasma ADMA to plasma arginine are
inadequately understood, but might include the requirement for protein-incorporated arginine
as the substrate for PRMTs that generate ADMA [16], upregulation of the cationic transporters
that allow both ADMA and arginine to cross cell membranes [61,62], and negative feedback of
arginine on DDAH activity [32].
DDAH1 is known to regulate ADMA/arginine homeostasis: heterozygous knock-out of
DDAH1 in mice increased plasma ADMA, decreased NO-dependent vasodilation, and ele-
vated blood pressure [63]. Conversely, transgenic over-expression of DDAH1 decreased
plasma ADMA concentrations, increased urinary nitrites/nitrates and decreased blood pres-
sure [64]. A second DDAH isoform (DDAH2) has been identified [65], but in contrast to
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DDAH1, suppression of DDAH2 expression did not result in altered plasma ADMA concentra-
tions [34]. The liver expresses DDAH1 [65] and metabolic tracer studies identified the liver as a
major site for clearance of circulating ADMA [37]. Induction of DDAH1 expression in liver
significantly lowered plasma ADMA [33]. Endothelial cell-specific knock-out of DDAH1
revealed hepatic DDAH1 expression not only in hepatic endothelial cells but also in hepato-
cytes [29,66], which appear to be primarily responsible for systemic ADMAmetabolism. More-
over, DDAH1 may regulate the release of ADMA from non-endothelial cell sources that affect
local ADMA levels and vascular function. Patients with hepatic failure had elevated plasma lev-
els of ADMA [38,67,68] that decreased after liver transplantation [67]. Conversely, patients
with acute rejection of their liver graft had elevated ADMA compared to patients without epi-
sodes of rejection [67]. Taken together, results from human patients and animal studies impli-
cate hepatic DDAH1 as a key regulator of circulating ADMA. In severe malaria, renal
insufficiency [17], in addition to the hepatic DDAH1 dysfunction we present here, could con-
tribute to dysregulation of ADMA/arginine homeostasis.
Plasmodium infection appears to accelerate the degradation of DDAH1 protein in hepatic
tissue. Oxidative stress is a potential trigger of DDAH degradation that is present during
malaria infection [69,70]. Overexpression of the p22phox subunit of NADPH oxidase in smooth
muscle cells increased oxidative stress, decreased DDAH protein levels, decreased DDAH
activity and caused accumulation of both intracellular and extracellular ADMA [71]. Treat-
ment of p22phox-transfected smooth muscle cells with the proteasome inhibitor epoxomicin
raised DDAH protein concentrations and reduced intracellular ADMA, demonstrating that
oxidative modification of DDAH protein may target it for degradation by the proteasome. Plas-
modium infection causes oxidative stress in liver tissue of mice [72], which could be sufficient
to accelerate the degradation of DDAH1 in liver endothelium.
The liver may be exposed to reactive oxygen species generated by the increased populations
of neutrophils and pigment-laden monocytes found in the hepatic vasculature during malaria
infection [72,73]. Increased cell-free heme due to hemolysis promotes neutrophil infiltration
and resulting liver damage [72], raising the possibility that hemolysis may contribute to hepatic
DDAH dysfunction. Hemolysis may also result in direct release of ADMA into circulation.
Human erythrocytes contain total (free plus protein-incorporated) ADMA concentrations in
the range of 47.85 ± 1.68 μmol/L, extrapolated from a concentration of 15.95 ± 0.56 μmol/L
reported for hydrolysates of erythrocyte samples diluted 1:3 in water [59]. Rat erythrocytes
contain a similar concentration of total ADMA, estimated to be 40.6 ± 7.2 μmol/L [74]. Follow-
ing hemolysis, methylated erythrocyte proteins are exposed to proteases that disproportion-
ately release ADMA relative to arginine [74,75]. Thus hemolysis could both increase ADMA
release and inhibit ADMA clearance by promoting DDAH degradation.
Elevation of ADMA relative to arginine favors NOS inhibition because ADMA is a competi-
tive inhibitor of NOS [14]. ADMA also competes with arginine for cellular uptake, which
could limit arginine availability for NO synthesis [61]. The intracellular concentration of
ADMA in endothelial cells is approximately 10-fold higher than extracellular levels, reaching a
concentration of 3–5 μmol/L which is near the Ki of eNOS [76,77]. Even small elevations in
extracellular ADMA concentration to 2 umol/L had profound effects on brain NOS activity
and gene expression profiles of endothelial cells in culture or in mice [78,79]. Impaired NO
synthesis has been implicated in impaired vasoregulation, loss of blood-brain barrier integrity
and cytoadherence of parasitized erythrocytes to the vascular endothelium during severe
malaria. In a mouse model, treatment with an NO-donor improved cerebral microcirculation,
reduced cerebral hemorrhages and prevented blood-brain barrier break-down [6,7]. NO
synthase inhibition by ADMA downregulates tight junction protein expression [24], which
may explain the beneficial effect of NO on endothelial barrier integrity. Impaired NO synthesis
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is associated with increased adhesion molecule expression [80] and L-NAME (a synthetic NOS
inhibitor) increased cytoadherence of parasitized red blood cells to vascular endothelial cells in
vitro [9]. Thus, impaired NO signaling may contribute to microhemorrhage, vascular leak and
sequestration of parasitized red blood cells observed in children with fatal cerebral malaria
[13]. Taken together, these findings suggest that disruption of ADMA/arginine homeostasis
could contribute to severe malaria pathogenesis by inhibiting NO synthesis.
Therapeutic strategies that preserve or enhance DDAH activity during Plasmodium infec-
tion are needed to establish a causal relationship between DDAH degradation and disruption
of ADMA/arginine homeostasis. While restoring ADMA/Arginine homeostasis might be nec-
essary to improve endothelial NO synthesis, it might not be sufficient: impaired endothelial
NO synthesis is likely to be limited by arginine deficiency and oxidation of tetrahydrobiopterin.
NO that is produced will have a limited half-life due to reactions with cell free hemoglobin,
superoxide, and other radicals that have increased abundance during malaria infection.
In summary, through clinical observational studies of Gambian children and controlled
experiments mice, we have identified hepatic DDAH dysfunction as a potential mechanism
disturbing ADMA/Arginine homeostasis and limiting nitric oxide synthesis in severe malaria.
Methods
Ethics Statement
Patient enrollment and sample collection were conducted following ethical review and
approval by the Gambian Government/MRC Joint Ethics Committee and the Ethics Commit-
tee of the London School of Hygiene & Tropical Medicine (SCC 670, SCC 1002, SCC 1003,
SCC 1077 & SCC 1113 [healthy children]). Analysis of plasma samples and de-identified clini-
cal data at the National Institutes of Health was exempted from further ethical review by the
NIH Office of Subjects Research (Exemption #5161). Written informed consent was provided
by a parent or guardian on behalf of children enrolled in the study. Families who declined to
participate were provided standard medical care.
Animal studies (described in detail in the supplementary information, S1 Methods) were
specifically approved by the National Institutes of Allergy and Infectious Diseases (NIAID)
Animal Care and Use Committee (ACUC) under the protocol identification LMVR 18E. The
NIAID ACUC complies with the U.S. Government Principles for the Utilization and Care of
Vertebrate Animals, the Public Health Service (PHS) Policy on Humane Care and Use of Labo-
ratory Animals, and the Animal Welfare Act.
Human Subjects and Sample Collection
Children with severe malaria or uncomplicated malaria were enrolled at health centers in a
peri-urban area around Fajara, The Gambia as previously described [81]. Enrollment sites
included the Royal Victoria Teaching Hospital, the Brikama Health Centre, the MRC Fajara
Gate Clinic and the Jammeh Foundation for Peace Hospital in Serekunda.
Acute uncomplicated malaria was defined as asexual P. falciparum parasitemia of>5000
parasites/μl detected by slide microscopy with an episode of fever (temperature>37.5°C)
within the previous 48 hrs and the absence of severe criteria. Acute severe malaria was defined
as parasitemia of>5000 parasites/μl, a history of fever and one or more of the following: severe
anemia (Hb< 6g/dl), severe acidosis (serum lactate>7 mmol/L), cerebral malaria (Blantyre
coma score 2 or less in the absence of hypoglycemia or hypovolemia with the coma lasting for
at least 2 hrs), and severe prostration (inability to sit unsupported in children>6 months or
inability to suck in children<6 months). Patients with severe malaria were admitted and
treated with quinine, and patients with uncomplicated malaria were treated with chloroquine
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plus sulfadoxine-pyrimethamine according to Gambian Government Treatment Guidelines
[82].
Ninety-six children with severe malaria and 102 children with uncomplicated malaria were
enrolled during the 2005–2008 malaria seasons. Four milliliters of blood were collected in hep-
arinized vacutainers (BD) at the time of initial presentation and at a follow-up visit 28 days
later. Blood samples were immediately refrigerated, placed on ice for transport, and processed
within 2 hours of collection. Plasma was frozen at -80°C. Three patients with severe malaria
died and 65 completed follow-up visits; plasma sample were available from 47 of them. Eighty-
five patients with uncomplicated malaria completed follow-up visits; plasma samples were
available from 65 of them. Thirty-one healthy, afebrile, aparasitemic Gambian children of simi-
lar ages were also studied at a single visit.
Clinical Laboratory Methods
P. falciparum parasitemia was determined by bright-field microscopy of giemsa-stained blood
smears. 50 fields were counted at high power. Full blood counts were obtained with an auto-
mated instrument (Clinical Diagnostics solutions, Inc., Fort Lauderdale, FL, USA). Lactate was
measured with a handheld Lactate Pro device (Arkray, Edina, MN, USA). Soluble VCAM
(sVCAM) and plasma haptoglobin concentrations were determined by ELISA (sVCAM: R&D
Systems, Minneapolis, MN, USA; haptoglobin: Alpco, Salem, NH, USA) according to the man-
ufacturer’s instructions.
P. falciparumHRP2 was measured in duplicate in plasma by ELISA (Cellabs) according to
the manufacturer’s instructions. A standard curve was constructed using serial dilutions of the
PfHRP2 standard and run with every plate. Laboratory staff were unaware of clinical status of
the subjects.
Determination of ADMA and Arginine in Human and Mouse Plasma
Each plasma sample was diluted in PBS containing NG-monoethyl-L-arginine (MEA) as an
internal standard before undergoing solid-phase extraction (Oasis MCX 96-well μElution
Plate, Waters Corporation, Milford, MA, USA). The eluted cationic amino acids were dried,
resuspended in water, and derivatized with ortho-phthalaldehyde (OPA) in 3-mercaptopropio-
nic acid. Derivatized samples were separated by reverse-phase liquid chromatography over a
1×100 mm C18(2) column (Phenomenex, Torrance, CA, USA) and fluorescence detected at
excitation and emission wavelengths of 340nm and 455nm, respectively. Concentrations were
determined by integrating peak area with reference to the internal standard (MEA) and daily
external standards (Arg, ADMA, and MEA).
Statistical Analyses
Data are expressed as median and inter-quartile range (IQR). Statistical analyses were per-
formed with GraphPad Prism 6.02 software and the R computing environment. P-values of
less than 0.05 were considered significant. Mann-Whitney test was used to compare median
values between healthy children and children with uncomplicated or severe malaria. Wilcoxon
matched-pairs signed rank test was used to compare acute and recovery values in children with
uncomplicated or severe malaria. Correlations were calculated on transformed data using Pear-
son’s correlation test, except in the case of correlation with haptoglobin in which Spearman’s
method was used. When two separate groups were combined, partial correlations were calcu-
lated. Multiple linear regression analysis was used to assess the independent contributions of
ADMA or arginine to correlations with hemoglobin, HRP2, sVCAM, or lactate. In these linear
models, arginine and ADMA were the explanatory variables, and the direction, strength and
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significance of the association was assessed by the beta value and p-value. Mann-Whitney test
was used to compare values between infected mice and uninfected controls. Data are available
in supplemental files S1 Data and S2 Data.
Supporting Information
S1 Table. Correlations between Hepatic DDAH Activity and Plasma ADMA/Arg or
Hepatic ADMA. Data are presented as Pearson’s correlation coefficients, partial correlation
coefficients and p-values. df, degrees of freedom. The results in rows (A) and (B) correspond to
S4C and S4D Fig.
(DOCX)
S2 Table. Correlations between Hepatic DDAHDensitometry and Plasma ADMA/Arg or
Hepatic ADMA. Data are presented as Pearson’s correlation coefficients, partial correlation
coefficients and p-values. df, degrees of freedom. The results in rows (C) and (D) correspond
to S4C and S4D Fig.
(DOCX)
S1 Fig. The relationship between Plasma ADMA and Arginine in Gambian Children. Pear-
son’s correlation coefficient, r, and p-value are provided in the upper left corner of each graph
of ADMA and arginine in healthy children (open circles, upper left panel), children with
uncomplicated malaria (orange circles, upper middle panel), and children with severe malaria
(red circles, upper right panel). Day 28 follow up values are presented in the lower panels. The
slopes of the linear regression models are presented in the lower right corner of each graph,
along with the p-value for F-tests comparing the slopes of each group as indicated.
(PDF)
S2 Fig. Two Alternative Models Depict How the ADMA/Arginine Ratio Changes as Argi-
nine Concentration Falls in Gambian Children. In the No Compensation model, ADMA
remains constant as arginine concentration falls, causing the ADMA/Arg ratio to rise accord-
ing to a reciprocal function. In the Full Compensation model, ADMA is regulated to maintain
a constant ADMA/Arg ratio in the setting of falling arginine concentration. The models are
based on ADMA and arginine measurements from healthy Gambian children (open circle
denotes geometric mean and bars the 95% confidence interval). During acute severe malaria,
children exhibit incomplete compensation of ADMA in the setting of hypoargininemia (red
circle), but they return to a compensated state by day 28 despite persistent hypoargininemia
(dark gray circle). Children with uncomplicated malaria also exhibit incomplete compensation
of ADMA in the setting of hypoargininemia and return to a compensated state by day 28
(orange and light gray circles), though the disturbance is less than observed in severe malaria.
Arrows indicate the shift from admission to day 28 values.
(PDF)
S3 Fig. Correlation Analysis of ADMA or Arginine with Hemoglobin, Haptoglobin, HRP2,
sVCAM, or Lactate in Gambian Children with Severe Malaria. X-y plots are presented to
support the correlation analyses detailed in Table 3 of the main text. ADMA, Arg, HRP2,
sVCAM were natural log-transformed. Lactate was square root-transformed. Hemoglobin and
haptoglobin were not transformed. Dotted lines represent the best fits of linear models relating
the x and y variables. Refer to Table 4 for multiple linear regression (MLR) analysis of the inde-
pendent associations of hemoglobin, HRP2, sVCAM and lactate with ADMA or arginine.
MLR analysis revealed that these correlations are primarily related to ADMA and not to
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arginine.
(PDF)
S4 Fig. Correlations between Measures of Hepatic DDAH Activity or Abundance and
Plasma ADMA/Arginine or Hepatic Tissue Levels of ADMA. Filled circles represent mea-
surements obtained from P berghei-infected mice; open circles represent measurements
obtained from uninfected control mice. Dotted line represents the linear regression of data
from infected mice and dashed line is from uninfected mice. Pearson’s r and p-values for the
correlations of each group and combined groups are provided in S1 and S2 Tables. The partial
correlation provides the combined correlation after accounting for the infected or uninfected
status of the animals. A, correlation of plasma ADMA/Arg with hepatic DDAH activity; B, cor-
relation of hepatic ADMA concentration with hepatic DDAH activity; C, correlation of plasma
ADMA/Arg with hepatic DDAH western blot densitometry fold change relative to uninfected
mice, normalized to GAPDH; and D, correlation of hepatic ADMA with hepatic DDAH west-
ern blot densitometry fold change relative to uninfected mice, normalized to GAPDH.
(PDF)
S5 Fig. Validation of DDAH Activity Assay. DDAH activity in liver homogenates was
assessed by quantifying citrulline production in the presence of saturating concentrations of
ADMA substrate (2.5 mmol/L). (A) After addition of 2.5 mmol/L of ADMA to liver homoge-
nate, citrulline increased linearly over time (R2 = 0.9972). This confirmed that ADMAmetabo-
lism is constant and approximates Vmax kinetics when 2.5 mmol/L ADMA is present.
Citrulline production was negligible in the absence of exogenous ADMA (PBS only 0 hr:
0.52 ± 0.19 μM, 2 hr: 0.39 ± 0.07 μM, p> 0.05). (B) Citrulline (25 μmol/L) was stable during a
2 hr incubation at 37°C (0 hr: 26.3 ± 1.6 μM, 2 hr: 25.3 ± 3.0 μM, p> 0.05), demonstrating that
citrulline is not degraded or metabolized by enzymes in liver homogenate and is thus a reliable
indicator of DDAH activity. (C and D) After addition of 2.5 mmol/L ADMA to liver homoge-
nate, the rate of citrulline production was linear with respect to the protein concentration of
liver homogenate in the assay (R2 = 0.9995 for line of best fit, 3 replicates for each homogenate
dilution).
(PDF)
S1 Methods. Supplemental Methods. Detailed description of animal experiments and labora-
tory methods are provided in the supporting information.
(PDF)
S1 Data. De-identified Clinical, HPLC, and ELISA Data from the Children Enrolled in the
Study. Data are provided in.csv format for inspection and analysis.
(CSV)
S2 Data. Data from P. berghei ANKA Infections in C57Bl/6 Mice. Data are provided in.csv
format for inspection and analysis.
(CSV)
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